Key terms
About INMB
INmune Bio, Inc. Is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprograms the immune system to fight cancer and Alzheimer’s disease. Its products include pipeline, INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell in September 2015 and is headquartered in Boca Raton, FL.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest INMB news
Mar 06
1:56pm ET
Buy Rating Affirmed for Inmune Bio Amid Promising Alzheimer’s Treatment Developments
Mar 05
8:11am ET
INmune Bio reports ‘significant’ EEG improvement in patients treated with Xpro
Feb 02
5:25am ET
BTIG Remains a Buy on Inmune Bio (INMB)
Feb 01
12:37am ET
Buy Rating Affirmed: Inmune Bio’s XPro Progresses with FDA’s Green Light and Unique Therapeutic Approach
Jan 31
12:35pm ET
Inmune Bio’s Buy Rating Affirmed Amid Positive Alzheimer’s Program Developments
Jan 30
8:05am ET
INmune Bio announces FDA removal of clinical hold for Alzheimer disease program
Jan 18
11:32am ET
Biotech Alert: Searches spiking for these stocks today
Jan 03
12:36pm ET
Buy Rating Affirmed for INmune Bio Amid Progress in Cancer Therapy Trials and Financial Stability
Jan 02
9:21am ET
Inmune Bio (INMB) Receives a Buy from BTIG
Jan 02
8:06am ET
INmune Bio doses first patient in Phase 1/2 study of INKmune
Dec 31
5:18am ET
BTIG Sticks to Its Buy Rating for Inmune Bio (INMB)
Dec 21
1:37am ET
Inmune Bio’s Stock Poised for Growth on Anticipated Regulatory Milestones and Clinical Trial Progress
Dec 20
6:00am ET
Analysts Offer Insights on Healthcare Companies: Inmune Bio (INMB) and Idexx Laboratories (IDXX)
Dec 18
4:08pm ET
INmune Bio announces Alzheimer’s trial remains on hold
No recent news articles are available for INMB
No recent press releases are available for INMB
INMB Financials
Key terms
Ad Feedback
INMB Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
INMB Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range